Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Abstract Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, d...

Full description

Bibliographic Details
Main Authors: Weijie Ma, Barbara M. Gilligan, Jianda Yuan, Tianhong Li
Format: Article
Language:English
Published: BMC 2016-05-01
Series:Journal of Hematology & Oncology
Subjects:
Cancer immunotherapy
Cytotoxic T cells
Immune checkpoint blockade antibodies
PD-1
PD-L1
Immune-related adverse events
Online Access:http://link.springer.com/article/10.1186/s13045-016-0277-y

Internet

http://link.springer.com/article/10.1186/s13045-016-0277-y

Similar Items